RLAY Stock Forecast: Relay Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$16
+1.32% on the day

The 12 Wall Street analysts covering Relay Therapeutics, Inc. hold a median 12-month price target of $29 — +79.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 80 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.6B
Ticker Nerd rank
80/ 100
Median analyst target
$29
Analysts covering
12
Revenue$350K−48.3% y/y
Operating income−$90.8M
Net income−$83.7M
Free cash flow−$54.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.9%
1M
−12.6%
YTD
+90.5%
1Y
+152.7%
From 52W high
−22.3%
From 52W low
+152.7%
$6
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Relay Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
80/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Value
87
Quality
77
Accruals
70
Revisions
63
Volatility
59
Growth
49
Issuance
41

Momentum (94): The shares have been drifting up relative to others.

Issuance (41): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RLAY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RLAY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26RLAYHigh $32Median $29Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12
Buy
0
Hold
0
Sell
$25
Low
$29
Median
$32
High

The green dot is the last close — the median target sits +79.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Nov 2026Jones TradingMaintainsBuy—
6 Nov 2026Jones TradingMaintainsBuy$20 → $31
20 Aug 2026HC Wainwright & Co.MaintainsBuy$28 → $29
14 Aug 2026JP MorganMaintainsOverweight$28 → $31
10 Aug 2026CitizensMaintainsMarket Outperform$21 → $26
7 Aug 2026BarclaysMaintainsOverweight$27 → $30
21 July 2026Goldman SachsMaintainsBuy$22 → $31
16 July 2026Canaccord GenuityInitiatesBuy$29
8 July 2026JP MorganInitiatesOverweight—
26 May 2026GuggenheimMaintainsBuy—
26 May 2026HC Wainwright & Co.MaintainsBuy—
20 May 2026BarclaysMaintainsOverweight—
20 May 2026CitizensMaintainsMarket Outperform—
19 May 2026Raymond JamesMaintainsStrong Buy—
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
28 Apr 2026CitizensMaintainsMarket Outperform—
28 Apr 2026Goldman SachsMaintainsBuy—
28 Apr 2026OppenheimerMaintainsOutperform—
28 Apr 2026Wells FargoMaintainsOverweight—
14 Apr 2026Jones TradingInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RLAY.

Market Radar

This page is one stock. Monday covers all of them.

RLAY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RLAY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Relay Therapeutics, Inc. returned +152.7% against +6.9% for the S&P 500, dividends included.

RLAY vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26RLAYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RLAY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
344.1×

Cheaper than 2% of US stocks

Price / book
4.3×

Cheaper than 21% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−41.2%

Higher than 24% of US stocks

Return on assets
−25.5%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Relay Therapeutics, Inc. has a market value of $3.6B and an enterprise value of $2.7B.

  • Revenue in the twelve months to 30 June 2026: $10.3M. The latest quarter shrank 48.3% year on year.

  • Net income over the same four quarters: −$286.0M, a −2763.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.57.

  • Free cash flow in the twelve months to 30 June 2026: −$212.2M.

  • Shares outstanding: 218.5M.

  • Relay Therapeutics, Inc. employs 218 people — $47K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

RLAY and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RLAYRelay Therapeutics, Inc.$3.6B80
PBLSParabilis Medicines, Inc.$3.4B2
XENEXenon Pharmaceuticals, Inc.$3.5B41
TNGXTango Therapeutics, Inc.$3.5B23
IRONDisc Medicine, Inc.$3.3B42
ELVNEnliven Therapeutics, Inc.$3.3B77
TARSTarsus Pharmaceuticals, Inc.$3.6B72

Take a look at RLAY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Relay Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RLAY

What is the RLAY stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Relay Therapeutics, Inc. have a median 12-month price target of $29, with estimates ranging from $25 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RLAY stock a buy right now?

Of the 12 analysts covering Relay Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relay Therapeutics, Inc. 80 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RLAY?

As at 21 Nov 2026, Relay Therapeutics, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will RLAY stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +79.9% from the last close, and Ticker Nerd's factor model ranks Relay Therapeutics, Inc. 80 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RLAY stock forecast for 2030?

No analyst covering Relay Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $32 over the next 12 months.

How has RLAY stock performed over the past year?

Relay Therapeutics, Inc. returned +152.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Relay Therapeutics, Inc. do?

Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease. The company uses its proprietary Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology in order to address protein targets that have been difficult to drug with conventional methods.

Company

About Relay Therapeutics, Inc.

Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease. The company uses its proprietary Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology in order to address protein targets that have been difficult to drug with conventional methods. Its current pipeline centers on targeted cancer programs, including candidates for genetically defined tumors, as well as selected genetic disease applications. Relay Therapeutics Inc. operates in the biopharmaceutical sector with a strong emphasis on precision oncology, where it aims to design more selective therapies for molecularly characterized diseases. Based in Cambridge, Massachusetts, the company works at the intersection of drug discovery technology and clinical development, making it a notable participant in the small-molecule precision medicine market.

CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS · 218 employees · United States · https://www.relaytx.com